Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon by Aghokeng, Avelin F. et al.
Inaccurate Diagnosis of HIV-1 Group M and O Is a Key
Challenge for Ongoing Universal Access to Antiretroviral
Treatment and HIV Prevention in Cameroon
Avelin F. Aghokeng
1,2*, Eitel Mpoudi-Ngole
1, Henriette Dimodi
1, Arrah Atem-Tambe
1, Marcel Tongo
1,
Christelle Butel
2, Eric Delaporte
2, Martine Peeters
2
1Virology Laboratory IMPM/IRD, Yaounde ´, Cameroon, 2UMR145, Institut de Recherche pour le De ´veloppement (IRD), University of Montpellier 1, Montpellier, France
Abstract
Background: Increased access to HIV testing is essential in working towards universal access to HIV prevention and
treatment in resource-limited countries. We here evaluated currently used HIV diagnostic tests and algorithms in Cameroon
for their ability to correctly identify HIV infections.
Methods: We estimated sensitivity, specificity, and positive and negative predictive values of 5 rapid/simple tests, of which
3 were used by the national program, and 2 fourth generation ELISAs. The reference panel included 500 locally collected
samples; 187 HIV -1 M, 10 HIV-1 O, 259 HIV negative and 44 HIV indeterminate plasmas.
Results: None of the 5 rapid assays and only 1 ELISA reached the current WHO/UNAIDS recommendations on performance
of HIV tests of at least 99% sensitivity and 98% specificity. Overall, sensitivities ranged between 94.1% and 100%, while
specificities were 88.0% to 98.8%. The combination of all assays generated up to 9% of samples with indeterminate HIV
status, because they reacted discordantly with at least one of the different tests. Including HIV indeterminate samples in test
efficiency calculations significantly decreased specificities to a range from 77.9% to 98.0%. Finally, two rapid assays failed to
detect all HIV-1 group O variants tested, with one rapid test detecting only 2 out of 10 group O specimens.
Conclusion: In the era of ART scaling-up in Africa, significant proportions of false positive but also false negative results are
still observed with HIV screening tests commonly used in Africa, resulting in inadequate treatment and prevention
strategies. Depending on tests or algorithms used, up to 6% of HIV-1 M and 80% of HIV-1 O infected patients in Cameroon
do not receive ART and adequate counseling to prevent further transmission due to low sensitivities. Also, the use of tests
with low specificities could imply inclusion of up to 12% HIV negative people in ART programs and increase budgets in
addition to inconveniences caused to patients.
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Introduction
Needs for HIV/AIDS care and treatment are increasing
continuously in resource-poor settings, especially in Africa where
the majority of people infected with HIV live. In addition to
provide treatment to HIV infected individuals, the World Health
Organization (WHO) and the Joint United Nations Programme
on HIV/AIDS (UNAIDS) recommend also that prevention of new
HIV transmissions should be considered as a key element of the
global strategy of fight against HIV/AIDS [1]. A recent study even
suggests that universal voluntary HIV testing and immediate
antiretroviral treatment (ART), combined with present prevention
approaches, could have a major effect on severe generalised HIV/
AIDS epidemics [2]. However, efficient implementation of these
prevention and care strategies require correct identification of
non-infected and infected people.
Because they were historically developed based on HIV-1
subtype B prototype strains, HIV tests initially showed limitations
to detect HIV-1 group O [3], but also some group M variants,
especially during the serological window period [4]. Considerable
efforts have been made to improve the performance of these
assays. Inclusion of HIV-1 group O antigens or the use of broadly
cross-reactive antigens reduced limitations related to the high
genetic diversity of HIV [5] and the simultaneous detection of
HIV antigens (p24) and anti-HIV antibodies by fourth generation
assays reduced the window period [6,7]. Despite these efforts, the
performance of certain serological assays is still suboptimal as
illustrated by some studies [8–10] and the high rate of HIV
indeterminate results generated by HIV serological tests remains a
major concern in African countries [11–13].
Current ART scale-up in developing countries is increasing the
demand for HIV testing, especially through decentralized services
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infrastructures are very common. For these reasons, there has been
a proliferation of new rapid tests produced by several companies
around the world, which must obtain the US Food and Drug
Administration and the European Community label before
introduction in US and Europe respectively, but are not subjected
to any regulation prior to use in African countries, where there are
generally selected and ordered by national programs based on cost
and not on their performance. There is thus a need to monitor
quality and reliability of these new tests. Cameroon is a country
with an extreme high HIV genetic diversity, where approximately
all known HIV-1 group M variants co-circulate, but also the more
divergent HIV-1 group O and N viruses [14,15]. Because of this
high genetic diversity, HIV diagnosis in Cameroon is challenging
and continues to require a specific attention.
In this report, we evaluated the performance of three HIV rapid
assays recently introduced and recommended as first line tests in
Cameroon by the government. They were selected because of
their lower cost and without any prior evaluation on a local serum
panel. We also reassessed the performance of two other rapid
assays that we evaluated six years ago in Cameroon and which are
still used in certain settings, and two fourth generation ELISAs,
frequently used as reference assays in the region. Our study
illustrates that despite the ongoing scale-up of ART in Africa, a
significant proportion of false positive and also false negative
results are observed with HIV screening tests locally used.
Materials and Methods
Reference Sample Panel
Between July and December 2007, we constituted a plasma
panel by using discarded blood units from the blood bank of the
Central Hospital in Yaounde ´, the capital city of Cameroon.
According to the local recommendations, blood and blood
products intended for medical use, as transfusion, should be free
of antibodies to HIV, hepatitis C virus (HCV), hepatitis B virus
(HBV), and syphilis infections. Therefore, we collected from the
blood bank all blood units labeled as ‘‘discarded’’ due to presence
of at least one of these pathogens to constitute the reference sample
panel. A total of 490 anonymous samples tested by the blood bank
as HIV positive (n=241) or HIV negative (n=249) were collected.
The initial HIV status of these samples was based on the results of
HIV assays performed by the blood bank which were variable
during this time period and included the Genscreen HIV-1/HIV-
2 plus (Bio-Rad, Hercules, CA), HIV-1+2 Ag/Ab (Fortress
Diagnostics Limited, Antrim, UK), HIV(1+2) Rapid Test Strip
(KHB Shanghai Kehua Bioengineering Co. Ltd), and Determine
HIV-1/2 (Inverness Medical Innovations Inc., Waltham, MA).
Upon arrival at the Virology Laboratory IMPM/IRD, (Yaounde ´,
Cameroon), plasma was aliquoted for all samples and stored at
220uC and a buffy-coat layer, containing high concentrations of
leukocytes, was also collected from each sample and stored at
220u.
We also constituted a specific HIV-1 group O panel comprising
10 left over specimens of previously identified group O infected
patients confirmed by PCR and sequence analysis. All specimens
of this HIV-1 group O panel were collected less than one year
prior to the evaluation and only vials that were never thawed in
the past were used for the present evaluation.
Serological Testing and Evaluation of the Different HIV
Serological Assays
All the plasma samples of the reference panel were tested in
parallel with 5 HIV rapid tests and 2 fourth generation ELISAs, all
commercially available in Cameroon. Table 1 summarizes the
characteristics of all serological tests used. The rapid tests used
included: Retrocheck HIV (Qualpro Diagnostics, Goa, India), SD
Bioline HIV 1/2 3.0 (Standard Diagnostics Inc., Kyonggi-do,
South Korea), HIV(1+2) Rapid Test Strip (KHB Shanghai Kehua
Bioengineering Co. Ltd), Determine HIV-1/2 (Inverness Medical
Innovations Inc., Waltham, MA), and ImmunoComb II HIV 1&2
BiSpot (Orgenics LTD., Yavne, Israel). The two fourth generation
ELISAs, detecting simultaneously anti-HIV antibodies and HIV
antigens, were Enzygnost HIV Integral II (DADE BEHRING,
Table 1. Characteristics of the HIV diagnostic assays evaluated as described by manufacturers.
Test name Manufacturer Assay type Antibody and antigen used Sample type Local price ($)
Simple/rapid
Retrocheck HIV Qualpro Diagnostics,
Goa, India
Immunochromatographic assay HIV1 (gp41, p24) and HIV2
(gp36) recombinant proteins
Serum/plasma/
whole blood
0.8 $
SD Bioline HIV 1/2 3.0 Standard Diagnostics Inc.,
Kyonggi-do, South Korea
Immunochromatographic assay HIV1 (gp41, p24) and HIV2
(gp36) recombinant proteins
Serum/plasma/
whole blood
1.9 $
HIV(1+2) Rapid Test Strip KHB Shanghai Kehua
Bioengineering Co. Ltd
Immunochromatographic assay HIV-1 and HIV-2 Serum/plasma/
whole blood
0.7 $
Determine HIV-1/2 Inverness Medical Innovations
Inc., Waltham, MA
Immunochromatographic assay Recombinant and synthetic
peptides
Serum/plasma/
whole blood
1.1 $
ImmunoComb II HIV 1&2
BiSpot
Orgenics LTD., Yavne, Israel Dot immunoassay HIV-1and HIV-2 synthetic
peptides
Serum/plasma 2.4 $
ELISA
Enzygnost HIV Integral II DADE BEHRING, Marburg,
Germany
Sandwich ELISA HIV-1 gp41, O gp41, and HIV-2
gp36 proteins and peptides
Serum/plasma 4.5–5 $
Murex HIV Ag/Ab-
Combination
Murex Biotech Ltd, Kent, UK Sandwich ELISA HIV-1 Env and Pol, HIV-2 Env,
HIV-1 O recombinant proteins
Serum/plasma 4.5–5 $
LIA
l’Inno-Lia HIV I/II Score Innogenetics, Gent, Belgium Blot Recombinant proteins and
synthetic peptides
Serum/plasma 40–45 $
doi:10.1371/journal.pone.0007702.t001
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(Murex Biotech Ltd, Kent, UK). Two rapid tests, Determine
and ImmunoComb II, were undergoing a reevaluation six years
after their first evaluation in Cameroon [11], while the three
others were assessed for the first time in Cameroon. A line
immunoassay, Inno-Lia HIV I/II Score (Innogenetics, Gent,
Belgium), was used as a confirmatory assay. All assays were
performed according to the manufacturers’ instructions.
Samples that scored negative in all 7 screening assays (rapid tests
and ELISAs) were considered as HIV negative. Samples positive
to all screening assays were classified as HIV positive. Samples
with discordant results among the different rapid tests and ELISAs
were further tested with the confirmatory assay, Inno-Lia HIV,
and classified based on the confirmation result. Specimens that
reacted discordantly with screening assays and were neither
confirmed as positive nor as negative with the confirmatory test
were considered HIV indeterminate, and were further tested with
a highly sensitive polymerase chain reaction (PCR) to detect
present of HIV proviral DNA as mentioned below. All HIV
positive samples from the reference panel were subjected to an in-
house V3-loop peptide ELISA to discriminate between HIV-1
group M, O, and N, and HIV-2 as described previously [16,17].
Confirmatory PCR Analyses
PCR testing was done on all samples that were considered as
HIV indeterminate because they reacted discordantly with the
screening assays and were not successfully confirmed as HIV
positive or negative using the Inno-lia confirmatory assay. Proviral
DNA was extracted from uncultured peripheral blood mononu-
clear cells (PBMCs) contained into the collected buffy-coat layers
using the QIAamp DNA Blood mini kit (Qiagen, Courtaboeuf,
France) as manufacturer’s instruction recommends. For PCR
testing, several sets of previously described universal and highly
sensitive primers known to amplify a large variety of HIV and SIV
strains in the pol region were used [18–20].
Statistical Analyses
The performance of the assays was expressed in terms of
sensitivity, specificity, efficiency, and negative and positive
predictive values. The 95% confidence intervals (CI) of the
estimated sensitivities, specificities and efficiency were also
calculated. For performance determination and CI calculation,
previously described formulas were used [11]. Negative and
positive predictive values (NPV and PPV) were determined based
on 5.5% HIV prevalences reported in 2004 from the last
population based survey in Cameroon [21]. The default scenario
when determining the performance of the different assays
excluded samples with indeterminate results as recommended by
WHO [22], but in addition we also estimated the performance
with these samples included, and in this case, we assumed that they
represent negative samples because of the absence of HIV proviral
DNA detection by PCR, and therefore most likely represent false
positive reactivities. Finally, we evaluated the performance of the
national HIV testing algorithm in use in Cameroon at the time of
the assays evaluation.
Ethical Considerations
The study was considered as a routine program evaluation and
quality monitoring of HIV diagnosis and the Cameroonian
Ministry of Health, which co-funded the study, do not recommend
any ethics approval in such conditions, especially when no human
subject is involved. All samples were anonymously obtained from
uncorrelated-discarded blood units to develop the reference
sample panel and no human experimentation was conducted.
Results
Characteristics of the Reference Sample Panel
A total of 490 plasma samples, collected at the blood bank, were
tested in parallel using 5 simple rapid assays and 2 fourth
generation ELISAs. 259 samples were confirmed as HIV negative
because they scored negative with all the 7 screening assays
(n=204) or reacted discordantly with at least one assay but were
further confirmed negative with the Inno-Lia HIV confirmatory
test (n=55). Similarly, 187 samples were confirmed HIV positive
because they scored positive to all the 7 screening assays (n=177)
or displayed discordant results with the screening assays and were
further confirmed positive with the Inno-Lia HIV confirmatory
assay (n=10). A total of 44 samples representing 9% of our sample
panel, were considered as HIV indeterminate, because of
discordant results among the 7 screening assays and lack of
criteria to identify HIV positivity or negativity in the confirmatory
Inno-Lia test. Interestingly, all attempts to identify proviral HIV
DNA in these 44 indeterminate samples using universal and
broadly sensitive PCR primers were unsuccessful. Analyses of
positive samples (n=187) with the discriminatory V3-loop peptide
ELISA identified all as HIV-1 group M variants.
Performance of Evaluated HIV Screening Assays to Detect
HIV-1 Group M Variants
Two distinct scenarios were used to determine the performance
of the evaluated assays. We first excluded samples with an
indeterminate HIV serology to comply with WHO guidelines
when evaluating HIV screening assays, and considered only
samples for which we obtained a definite HIV negative or positive
status. A total of 446 samples, including 187 HIV positive and 259
HIV negative where considered in this first scenario to calculate
sensitivity, specificity, efficiency, and PPV and NPV. However,
based on our previous experience and reports on the relative high
proportions of indeterminate results of HIV serological screening
assays in Africa, we also evaluated the performance of the assays
including indeterminate results. When included, we considered
these indeterminates (n=44) as negative since all attempts to
confirm HIV infection with molecular assays were unsuccessful.
The total sample size for the second scenario was 490, with 187
HIV positive and 303 HIV negative.
Amongthe 5rapidtests,only2,Determineand ImmunoCombII
displayed 100% (187/187) sensitivity. Retrocheck showed the
lowest sensitivity, 94.1% (176/187) only, since 11 HIV-1 group M
positive samples out of 187 were not detected. SD-Bioline and
HIV(1+2) Strip each missed 5 positive HIV-1 group M specimens
and showeda final sensitivity of 97.3% (182/187) (Table 2).Noneof
the 2 ELISAs had 100% sensitivity; Enzygnost missed 1 positive
specimen and consequently showed a sensitivity of 99.5%(186/187)
while Murex showed a sensitivity of 98.9% (185/187) because it
failed to detect 2 positive HIV-1 group M specimens (Table 2).
Assays sensitivities were not affected by addition of indeterminate
samples since we included these samplesas HIVnegatives (Table 3).
Overall, specificities of the tests ranged from 88.0% (228/259)
for Determine to 98.8% (256/259) for HIV(1+2) Strip for simple
rapid tests. The fourth generation ELISAs displayed specificities of
96.1% (249/259) for Murex and 98.5% (255/259) for Enzygnost
(Table 2). Inclusion of samples with indeterminate results
dramatically affected these specificities for all tests. Indeed, since
we included these samples as negatives, assays with lowest
specificity were significantly affected because they tend to generate
high levels of false positive results. The most affected rapid tests
were Determine, which showed a specificity of only 77.9% (236/
303) in this scenario, ImmunoComb with 78.9% (239/303), and
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strongly affected with inclusion of indeterminate results and
showed specificities of 90.1% (273/303) and 93.7% (284/303)
respectively (Table 3).
As a consequence of the low specificities, the overall assay
efficiencies were also low, ranging between 93.9% (415/446) for
Determine and 98.2% (438/446) for HIV(1+2) Strip for rapid
tests. The two ELISAs also showed relatively low efficiency, 98.9%
(441/446) for Enzygnost and 97.3% (434/446) for Murex
(Table 2). As expected, inclusion of indeterminate results
negatively affected the efficiency of all assays evaluated because
of the decrease in specificities (Table 3). Although we observed
good NPV for all the assays, between 99% and 100%, obtained
PPV were very low in both scenarios, with and without
indeterminate results (Table 2 & 3).
Detection of HIV-1 Group O Samples
We assessed the ability of the 7 screening assays to detect HIV-1
group O infection which represents about 1% of HIV-1 infections
in Cameroon [14,17]. Although we used only 10 HIV-1 O positive
samples, results obtained helped to identify assays capable to
detect this HIV-1 variant. The two ELISAs and three rapid tests,
Determine, ImmunoComb II, and SD Bioline correctly identified
all group O specimens. However, HIV(1+2) Strip missed 2 positive
samples while Retrocheck missed 8 samples out of 10 tested.
Performance of the Two Most Commonly Used National
HIV Testing Algorithms in Cameroon
At the time of this evaluation, the national strategy in use in
Cameroon for routine HIV diagnosis included two consecutive
rapid tests; Retrocheck being used as the first screening test and
Table 2. Performance of HIV assays evaluated, indeterminate result samples excluded.
HIV assay Total
a
HIV
positive
HIV
negative
True
positive
False
negative
True
negative
False
positive
Sensitivity
% (95% CI)
b
Specificity
% (95% CI)
Efficiency
% (95% CI)
PPV %
(5.5%)
d
NPV %
(5.5%)
Simple/rapid
Retrocheck HIV 446 187 259 176 11 255 4 94.1 (89.8–96.7) 98.5 (96.1–99.4) 96.6 (94.5–98.0) 78.1 99.7
SD Bioline HIV 1/2 3.0 446 187 259 182 5 240 19 97.3 (93.9–98.9) 92.7 (88.8–95.3) 94.6 (92.1–96.4) 43.6 99.8
HIV(1+2) Rapid Test
Strip
446 187 259 182 5 256 3 97.3 (93.9–98.9) 98.8 (96.6–99.6) 98.2 (96.5–99.1) 83.0 99.8
Determine HIV-1/2 446 187 259 187 0 228 31 100.0 (98.0–100.0) 88.0 (83.5–91.4) 93.0 (90.3–95.1) 32.7 100.0
ImmunoComb II HIV
1&2
446 187 259 187 0 232 27 100.0 (98.0–100.0) 89.6 (85.3–92.7) 93.9 (91.3–95.8) 35.8 100.0
ELISAs
Enzygnost HIV
Integral II
446 187 259 186 1 255 4 99.5 (97.0–99.9) 98.5 (96.1–99.4) 98.9 (97.4–99.5) 79.9 99.9
Murex HIV Ag/
Ab-Combo
446 187 259 185 2 249 10 98.9 (96.8–99.7) 96.1 (93.0–97.9) 97.3 (95.4–98.5) 59.9 99.9
aTotal number of samples included in the calculations.
b95% confidence intervals.
dGeneral population HIV prevalence reported in Cameroon in 2004.
doi:10.1371/journal.pone.0007702.t002
Table 3. Performance of HIV assays evaluated, indeterminate result samples included.
HIV assay Total
a
HIV
positive
HIV
negative
True
positive
False
negative
True
negative
False
positive
Sensitivity %
(95% CI)
b
Specificity %
(95% CI)
Efficiency %
(95% CI)
PPV %
(5.5%)
d
NPV %
(5.5%)
Simple/rapid
Retrocheck HIV 490 187 303 176 11 297 6 94.1 (89.8–96.7) 98.0 (95.7–99.1) 96.5 (94.5–98.0) 73.5 99.7
SD Bioline HIV 1/2 3.0 490 187 303 182 5 275 28 97.3 (93.9–98.9) 90.8 (87.0–93.5) 93.3 (90.7–95.2) 38.0 99.8
HIV(1+2) Rapid Test
Strip
490 187 303 182 5 298 5 97.3 (93.9–98.9) 98.4 (96.2–99.3) 98.0 (96.3–98.9) 77.4 99.8
Determine HIV-1/2 490 187 303 187 0 236 67 100.0 (98.0–100.0) 77.9 (72.9–82.2) 86.3 (83.0–89.1) 20.8 100.0
ImmunoComb II HIV
1&2
490 187 303 187 0 239 64 100.0 (98.0–100.0) 78.9 (73.9–83.1) 86.9 (83.7–89.6) 21.6 100.0
ELISAs
Enzygnost HIV
Integral II
490 187 303 186 1 273 30 99.5 (97.0–99.9) 90.1 (86.2–93.0) 93.7 (91.2–95.5) 36.9 99.9
Murex HIV Ag/Ab-
Combo
490 187 303 185 2 284 19 98.9 (96.8–99.7) 93.7 (90.4–96.0) 95.7 (93.5–97.2) 47.9 99.9
aTotal number of samples included in the calculations.
b95% confidence intervals.
dGeneral population HIV prevalence reported in Cameroon in 2004.
doi:10.1371/journal.pone.0007702.t003
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algorithm was applied on the reference panel of HIV-1 group M
samples to determine its performance in terms of sensitivity and
specificity. As expected, the algorithm sensitivity was quite close to
the sensitivity of the first screening assay, Retrocheck, with a value
of only 94.7%. The specificity of the algorithm was also not
satisfactory, since we obtained a value of 98.8%. In other words,
results of the algorithm performance show that when people were
tested in Cameroon using this strategy, 6 out of 100 persons were
falsely declared HIV negative, and 2 out of 100 persons were
falsely declared HIV positive. Just for illustration, 2% false HIV
positive individuals in a high burden country as South Africa with
more than 5 million HIV infections will correspond to about
100000 people falsely declare HIV positive. Moreover, it should be
noted that this algorithm can only detect 2 HIV-1 group O
variants out of 10, since the first assay used is Retrocheck. At the
level of a population, these results can have a strong negative
impact on the outcome of currently implemented HIV prevention,
care, and treatment programs.
In addition, the other algorithm commonly used in Cameroon,
which included Determine and ImmunoComb II in a serial
approach, Determine being the first or screening assay, while
ImmunoComb II was used to confirm positive and indeterminate
results also showed poor results. In fact, this strategy correctly
detected all HIV positive samples and showed sensitivity of 100%,
but because of the reduced specificity of both rapid assays, the
algorithm that combined the two rapid tests generated many false
positive results with and overall specificity of 91.5%. Therefore,
using this algorithm as a national testing strategy will reduce the
chance of having false negative results, but will dramatically
increase the number of people falsely tested positive, and perhaps
referred for a treatment initiation although they are HIV negative.
This latter could increase budget for ART treatment at
government levels in addition to all other indirect costs related
to antiretroviral treatment and disagreements caused to the
patients.
Discussion
Reliable HIV testing is a critical entry point to life-sustaining
healthcare services for people living with HIV and AIDS including
ART services and implementation of prevention strategies. Based
on current WHO/UNAIDS estimates, more than 80% of people
living with HIV in low and middle-income countries do not know
that they are infected and current guidelines recommend new
options to increase the provision of HIV testing as the so called
‘‘opt-out’’ approach to provider-initiated HIV testing and
counseling [1]. However, quality monitoring and assessment of
HIV testing in these settings is lacking, and very few is known
about the proportion of people falsely declared positive or negative
because of reduced performance of assays or inappropriate HIV
testing and its impact on current prevention and treatment
strategies in resources-constrained settings.
In resource limited countries, WHO recommends a testing
algorithm without the expensive confirmatory tests like western
blot or Inno-Lia. Ideally, the first assay should thus have a 100%
sensitivity combined to a good specificity and the second test used
to confirm the initial positive results should have a 100%
specificity coupled to a good sensitivity. None of the ELISAs
and only two out of five rapid assays (Determine and Immuno-
Comb II) here evaluated showed a 100% sensitivity, and none of
the 7 assays has a 100% specificity. Even the WHO and UNAIDS
recommendations which propose that HIV tests should have a
sensitivity of at least 99% and a specificity of 98% are not reached
by the assays from our study [1]. In addition, we here showed that
certain tests, not only fail to identify HIV infection with divergent
HIV-1 group O but also with common HIV-1 group M variants
circulating in Africa. This is in particular the case for recently
developed assays which are available at low costs in resource-
limited countries like Retrocheck, HIV(1+2) Rapid Test Strip,
etc… Sensitivity of HIV diagnostic tools has been considerably
increased to reduce the window period from weeks to days with
the fourth generation ELISAs, but our study shows that these tests
also fail to detect some HIV-1 group M infections. On the other
hand, we showed also problems with the specificity of assays
intended for confirmation in resource limited settings where
implementation of confirmatory assays like Western Blot or
Innolia was very early proven to be challenging because of the
required logistics and the high cost [22]. Evaluation of alternative
HIV testing strategies that do not include western blot has clearly
shown that adequate combination of rapid and/or ELISA tests
can have similar efficacy and even better than the reference
strategies using the western blot [23]. However, as the results of
our study here show, highly specific rapid assays and ELISAs are
becoming increasingly rare and developing an HIV testing
algorithm that combines good sensitivity and specificity in
resource-limited countries can be challenging. This was well
illustrated by the performance of the algorithm including
Determine and ImmunoComb II that we tested, which showed
very good sensitivity, but a low specificity with an overall false-
positive rate close to 10%. Similar findings were recently reported
from the Democratic Republic of Congo where a Me ´decins Sans
Frontie `res team found that the local HIV testing strategy using two
rapid assays, Determine and UniGold HIV (Trinity Biotech,
Wicklow, Ireland) generated up to 10.5% false positive results
[24]. Although low HIV prevalence can alter the characteristics of
diagnostic assays by increasing the proportion of false positives,
these findings suggest that current rapid testing strategies in
resource limited countries which frequently involves the use of two
sequential rapid tests should be correctly evaluated before
implementation by programs at the national level, not only to
limit the chance of having false negative HIV results, but also to
make sure that people declared as HIV positive, who are often
directly referred to treatment initiation, are really HIV infected.
Moreover, we showed that certain tests, like ImmunoComb II,
previously found as having a good specificity had a significant
decreased specificity over time, stressing the need for regular
evaluations also for known tests. This correct evaluation of rapid-
testing algorithms prior to use is essential in countries as
Cameroon where, because of cost limitations, HIV confirmatory
tests or additional testing by cheaper ELISAs are not routinely
recommended before treatment initiation.
The second problem we here highlighted is the difficulty for
decision/policy makers of AIDS programs to implement appro-
priate HIV testing policies in resource-poor countries. Good
practices recommend that HIV assays intended for use in a
country should be first evaluated on a serum panel from patients
infected with local and contemporary HIV strains to measure their
performance, but also for their operational characteristics as
storage conditions, equipment required, ease of use, etc. [1].
Unfortunately, this scenario is rarely applied due to practical
constraints, limited resources, inappropriate policies and absence
of laboratory experts in policymaking and program planning. In
practice, test kits are selected and ordered by government officials
with no or low experience in HIV diagnosis and selection is often
only based on the lower price and not also on tests efficacy. Lack of
national quality control policies including regular reassessment of
tests used in the country, is also a major concern [25]. Also,
HIV Testing in Africa
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also frequent and as a consequence, when existing, HIV testing
algorithms are not applied and testing strategies are based on
assays available as illustrated by the blood bank in Cameroon
where we collected the samples for our serum panel. Inaccuracy of
HIV diagnosis in the field is also often related to the fact that the
staff in the health care facility is not adequately trained, a high
turn over of personnel, the use of tests after expiration dates, or
shipment of tests in sub-optimal conditions. The responsibility of
funding agencies is a concern too, because they require numerous
financial and administrative conditions for money use, but they
rarely require quality monitoring and assessment of implemented
programs as key indicators to evaluate the appropriate use of
fundings.
In conclusion, our results showed that HIV diagnosis is still a
major challenge in Cameroon, a country with a general
population HIV prevalence of 5.5%, ranging from 2% in the
Nord Region to 8.6% and 8.7% in the East and Nord-West
Regions respectively [21]. There is a need to implement guidelines
and provide resources for the validation of national testing
strategies for HIV diagnosis on a regularly basis over time. Our
observations in field conditions in Cameroon and other African
countries stress also the urgent need for continuous training of
laboratory personnel or health care workers performing HIV
testing as well as for implementation of quality control programs to
improve the quality of results obtained with these basic HIV tests
in health care centers. The presence of laboratory experts in
program planning and policymaking could significantly improve
quality of HIV diagnosis.
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